Figure 3.

Associations of baseline (off-treatment) log urinary 11-dehydro-thromboxane B₂ with outcomes (A, B and C as in Figure 2). Adjusted for treatment allocation, basic factors, and predictors of log urinary 11-dehydro-thromboxane B₂. Model estimates and their floating absolute risk confidence intervals are plotted at the overall geometric mean urinary 11-dehydro-thromboxane B₂ within quartile and randomized treatment allocation, with the placebo and aspirin arms offset by ±0.05 log urinary 11-dehydro-thromboxane B₂ respectively to ensure the confidence intervals are distinguishable. The hazard ratio per 1 SD of log urinary 11-dehydro-thromboxane B₂ is constrained to have the same slope in both placebo- and aspirin-allocated arms. SD of log urinary 11-dehydro-thromboxane B₂ is 0.622. Hence, 1 SD corresponds to an exp(0.622) = 1.862 fold higher urinary 11-dehydro-thromboxane B₂. CI, confidence interval; n, number of events; SD, standard deviation; U-TXM, urinary 11-dehydro-thromboxane B₂